Related Experiment Video
Updated: May 16, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
Colicin M, a peptidoglycan lipid-II-degrading enzyme: potential use for antibacterial means?
Thierry Touzé1, Hélène Barreteau, Meriem El Ghachi
1Laboratoire des Enveloppes Bactériennes et Antibiotiques, IBBMC, Université Paris-Sud, UMR 8619 CNRS, 91405 Orsay, France. thierry.touze@u-psud.fr
Abstract:
Colicins are proteins produced by some strains of Escherichia coli to kill competitors belonging to the same species. Among them, ColM (colicin M) is the only one that blocks the biosynthesis of peptidoglycan, a specific bacterial cell-wall polymer essential for cell integrity. ColM acts in the periplasm by hydrolysing the phosphoester bond of the peptidoglycan lipid intermediate (lipid II). ColM cytotoxicity is dependent on FkpA of the targeted cell, a chaperone with peptidylprolyl cis-trans isomerase activity. Dissection of ColM was used to delineate the catalytic domain and to identify the active-site residues. The in vitro activity of the isolated catalytic domain towards lipid II was 50-fold higher than that of the full-length bacteriocin. Moreover, this domain was bactericidal in the absence of FkpA under conditions that bypass the import mechanism (FhuA-TonB machinery). Thus ColM undergoes a maturation process driven by FkpA that is not required for the activity of the isolated catalytic domain. Genes encoding proteins with similarity to the catalytic domain of ColM were identified in pathogenic strains of Pseudomonas and other genera. ColM acts on several structures of lipid II representative of the diversity of peptidoglycan chemotypes. All together, these data open the way to the potential use of ColM-related bacteriocins as broad spectrum antibacterial agents.
Insights
Colicin M (ColM) inhibits bacterial cell wall synthesis by targeting lipid II. Its isolated catalytic domain shows enhanced activity, suggesting potential for broad-spectrum antibacterial agents.
Area of Science:
- Microbiology
- Biochemistry
- Molecular Biology
Background:
- Colicins are bacteriocins produced by Escherichia coli to inhibit competing strains.
- Colicin M (ColM) uniquely targets peptidoglycan biosynthesis, a crucial component for bacterial cell wall integrity.
- ColM's activity is dependent on the host cell's FkpA chaperone, which possesses peptidylprolyl cis-trans isomerase activity.
Purpose of the Study:
- To delineate the catalytic domain of ColM and identify its active-site residues.
- To investigate the role of FkpA in ColM maturation and activity.
- To explore the potential of ColM and related bacteriocins as novel antibacterial agents.
Main Methods:
- Protein engineering to dissect ColM into its catalytic domain and full-length form.
- In vitro enzymatic assays to measure ColM and its catalytic domain activity against lipid II.
- Bactericidal assays under conditions bypassing the FhuA-TonB import machinery.
Main Results:
- The isolated catalytic domain of ColM exhibited a 50-fold increase in in vitro activity against lipid II compared to full-length ColM.
- The catalytic domain demonstrated bactericidal activity independently of FkpA when the import mechanism was bypassed.
- ColM's activity was confirmed against diverse lipid II structures, reflecting varied peptidoglycan chemotypes.
Conclusions:
- ColM requires FkpA-driven maturation for its full cytotoxic effect, but this is not essential for the isolated catalytic domain's inherent activity.
- The catalytic domain of ColM represents a potent antibacterial agent effective against various peptidoglycan structures.
- ColM-related bacteriocins show promise as broad-spectrum antibacterial agents for therapeutic applications.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Biological Methods for Microbial Control
Inhibitors of Bacterial Protein Synthesis
Gene Regulation in Microbial Communities: Quorum Sensing
Clinical Significance of Antibiotic Resistance
Production of Antibiotics

